ESH MDS 2021 | Promising therapies on the horizon for MDS
Maria Teresa Voso, MD, University Tor Vergata Rome, Rome, Italy, discusses the future of treatment of myelodysplastic syndromes (MDS) at EHS MDS 2021. Dr Voso highlights new treatment regimens including azacitidine plus the BCL-2 inhibitor venetoclax, and magrolimab, an anti-CD47 monoclonal antibody therapy, which both appear to be efficient in TP53 mutated MDS. She also discusses the potential of CPX-351 (cytarabine-daunorubicin) therapy for patients with MDS who are eligible for allogeneic stem cell transplantation. Finally, Dr Voso discusses the potential of APR-246 plus azacitidine, which is currently being investigated in a Phase III trial (NCT03745716) for patients with TP53 mutated MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
